'It takes two to tango': Bridging the gap between country need and vaccine product innovation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
08
2019
accepted:
15
05
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
25
8
2020
Statut:
epublish
Résumé
Despite a growing global commitment to universal health coverage, considerable vaccine coverage and uptake gaps persist in resource-constrained settings. One way of addressing the gaps is by ensuring product innovation is relevant and responsive to the needs of these contexts. Total Systems Effectiveness (TSE) framework has been developed to characterize preferred vaccine attributes from the perspective of country decision-makers to inform research and development (R&D) of products. A proof of concept pilot study took place in Thailand in 2018 to examine the feasibility and usefulness of the TSE approach using a rotavirus hypothetical test-case. The excel-based model used multiple-criteria decision analysis (MCDA) to compare and evaluate five hypothetical rotavirus vaccine products. The model was populated with local data and products were ranked against decision criteria identified by Thai stakeholders. A one-way sensitivity analysis was performed to identify criteria that influenced vaccine ranking. Self-assessment forms were distributed to R&D stakeholders on the usability of the approach and were subsequently analysed. The model identified significant parameters that impacted on MCDA rankings. Self-assessment forms revealed that TSE was perceived as being able to encourage closer collaboration between country decision makers and vaccine developers. The pilot study demonstrates that it is feasible to use an MCDA approach to elicit stakeholder preferences and determine influential parameters to help identify the preferred product characteristics for R&D from the perspective of country decision-makers. It found that TSE can help steer manufacturers to develop products that are better aligned with country need. Findings will guide further development of the TSE concept.
Sections du résumé
BACKGROUND
Despite a growing global commitment to universal health coverage, considerable vaccine coverage and uptake gaps persist in resource-constrained settings. One way of addressing the gaps is by ensuring product innovation is relevant and responsive to the needs of these contexts. Total Systems Effectiveness (TSE) framework has been developed to characterize preferred vaccine attributes from the perspective of country decision-makers to inform research and development (R&D) of products. A proof of concept pilot study took place in Thailand in 2018 to examine the feasibility and usefulness of the TSE approach using a rotavirus hypothetical test-case.
METHODS
The excel-based model used multiple-criteria decision analysis (MCDA) to compare and evaluate five hypothetical rotavirus vaccine products. The model was populated with local data and products were ranked against decision criteria identified by Thai stakeholders. A one-way sensitivity analysis was performed to identify criteria that influenced vaccine ranking. Self-assessment forms were distributed to R&D stakeholders on the usability of the approach and were subsequently analysed.
RESULTS
The model identified significant parameters that impacted on MCDA rankings. Self-assessment forms revealed that TSE was perceived as being able to encourage closer collaboration between country decision makers and vaccine developers.
CONCLUSIONS
The pilot study demonstrates that it is feasible to use an MCDA approach to elicit stakeholder preferences and determine influential parameters to help identify the preferred product characteristics for R&D from the perspective of country decision-makers. It found that TSE can help steer manufacturers to develop products that are better aligned with country need. Findings will guide further development of the TSE concept.
Identifiants
pubmed: 32520934
doi: 10.1371/journal.pone.0233950
pii: PONE-D-19-22507
pmc: PMC7286512
doi:
Substances chimiques
Rotavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0233950Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccine. 2016 Dec 7;34(50):6236-6242
pubmed: 27836438
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):585-592
pubmed: 30092151
Vaccine. 2017 Jul 24;35(33):4064-4071
pubmed: 28647170
Vaccine. 2015 Jun 8;33 Suppl 2:B34-9
pubmed: 26022565
BMC Health Serv Res. 2015 Jul 09;15:262
pubmed: 26152122
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):43
pubmed: 30455602
Eur J Immunol. 2017 Dec;47(12):2017-2025
pubmed: 28861908
Health Syst Reform. 2016 Jan 2;2(1):61-70
pubmed: 31514655
Vaccine. 2017 Dec 14;35(49 Pt A):6793-6797
pubmed: 28566254
Pharmacoeconomics. 2017 Jul;35(7):727-740
pubmed: 28432642
Value Health. 2016 Mar-Apr;19(2):125-37
pubmed: 27021745
BMC Med Inform Decis Mak. 2018 Nov 1;18(1):90
pubmed: 30382826
Curr Med Res Opin. 2016;32(1):177-81
pubmed: 26471345
Vaccine. 2017 Jan 20;35 Suppl 1:A43-A45
pubmed: 28017435
Glob Public Health. 2012;7(9):931-45
pubmed: 22783872
Soc Sci Med. 2017 Sep;188:137-156
pubmed: 28772164
Vaccine. 2016 Mar 18;34(13):1489-1495
pubmed: 26626210